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BACKGROUND: We conducted the first analysis of viral microRNAs (miRNAs) in lung cancer, with a focus on Epstein–Barr virus (EBV).
METHODS: We evaluated viral miRs with a two-channel oligo-array targeting mature, anti-sense miRNAs in 290 cases. In 48 cases, we
compared microarray and real-time quantitative PCR (qPCR) expression for three EBV miRNAs. We tested for EBV DNA, RNA, and
protein in tumour tissue from six cases with and six cases without strong qPCR-based evidence of EBV miRNAs.
RESULTS: The EBV miRNAs strongly differentiated between adenocarcinoma and squamous cell carcinoma using the microarray
(Po0.01 for 9 out of 16 EBV miRNAs). However, microarray and qPCR measurements of BART1, BART2, and BHRF1–3
expression were not significantly correlated (P¼ 0.53, 0.94, and 0.47, respectively). Although qPCR provided substantial evidence of
EBV miRNAs in 7 out of 48 cases, only 1 of these 7 cases had detectable EBV DNA in tumour tissue. None had detectable EBV RNA
or protein by histochemical stains.
CONCLUSION: In a comprehensive evaluation of EBV miRNA, DNA, RNA, and protein in lung cancer, we found little evidence of EBV
in lung tumour tissue. Discrepancies between microarray- and qPCR-based strategies highlight the difficulty of validating molecular
markers of disease. Our results do not support a role of EBV in lung cancer.
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Lung cancer is the most common cause of cancer death in the
world (Parkin et al, 2005). Although smoking is the primary
aetiologic agent, only 10–20% of smokers develop lung cancer
(Thun et al, 2002), and other cofactors that influence susceptibility
are an area of intense investigation. In addition, lung cancer is
estimated to be the seventh most common cause of cancer death
worldwide in never smokers, a population in which risk factors for
lung cancer are not well understood (Sun et al, 2007).
Infectious agents are hypothesised to contribute to lung cancer
carcinogenesis (Engels, 2008). This hypothesis may be most
plausible for lung adenocarcinoma, which occurs more often at
younger ages and in never smokers and women than squamous
cell carcinoma, and is histologically similar to ovine pulmonary
adenocarcinoma, a type of lung cancer in sheep caused by
jaagsiekte sheep retrovirus (Sun et al, 2007). This example of viral-
related lung cancer in sheep suggests that viruses might also
contribute to lung carcinogenesis in humans.
Epstein–Barr virus (EBV), a herpesvirus classified as a group 1
carcinogen by the International Agency for Research in Cancer
(Bouvard et al, 2009), has been proposed as a risk factor for lung
cancer. Epstein– Barr virus is clearly associated with lymphoma
and nasopharyngeal carcinoma (Kutok and Wang, 2006). It has
also been implicated in B10% of gastric cancers (Young and
Rickinson, 2004). Although lung cancer cases in serological studies
had higher EBV seropositivity than healthy controls (Desgranges
and de-The, 1979; Roy et al, 1994), previous studies of EBV in lung
tumour tissue have generally produced negative results, except in
rare cases of lymphoepithelioma-like carcinomas (LELCs) (Chu
et al, 2004; Lim et al, 2009). However, previous studies largely
tested for expression of EBV-encoded small RNA (EBER), which is
generally abundantly expressed in cells with latent EBV infection
but occasionally may be absent or heterogeneously expressed in
EBV DNA-positive tumours (Iwakiri and Takada, 2010).
A novel way to assess the involvement of infections like EBV is
to look for viral microRNAs (miRNAs) (Lagana et al, 2010). The
miRNAs are small, single-stranded RNAs that regulate gene
translation and are involved in many biological processes,
including immune system development and inflammatory
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responses (Schetter et al, 2010). Viral miRNAs regulate viral gene
expression and may also affect the expression of host genes, such
as those involved in cellular proliferation and apoptosis, thereby
potentially affecting cancer development and progression (Lagana
et al, 2010). Given the stability of miRNAs even in archival tissue
(Koshiol et al, 2010), miRNA expression might be a useful way to
screen for cancer-related infections.
To our knowledge, no previous study has tested for viral miRNA
expression in lung cancer. We evaluated viral miRNA expression
in the Environment And Genetics in Lung cancer Etiology
(EAGLE) study using two independent viral miRNA expression
assays: a miRNA microarray chip and real-time quantitative PCR
(qPCR). However, results from different miRNA expression
platforms are not always consistent using the same biologic
specimens (Koshiol et al, 2010). In addition, viruses like EBV may
be present in the infiltrating lymphocytes rather than the tumour
cells themselves. Thus, we also tested for EBV DNA and looked for
histochemical evidence of viral RNA and protein localisation to the
tumour cells or infiltrating lymphocytes of lung cancer cases.
MATERIALS AND METHODS
Study population
As previously described (Landi et al, 2008), EAGLE is a
population-based case–control study of 2100 consecutive incident
lung cancer cases and 2120 age-, sex-, and residence-frequency-
matched population controls, all Caucasians, enroled from 2003 to
2005 in northern Italy. Institutional Review Boards at the National
Cancer Institute and all other participating institutes gave
approval, and each subject signed an informed consent form.
Paraffin-embedded tissue blocks were available for 656 patients.
Patients who received chemotherapy or radiation therapy before
tissue collection, had tumours with mixed histologies or histolo-
gies other than adenocarcinoma or squamous cell carcinoma, or
had insufficient tumour tissue were excluded. The current study
included all remaining adenocarcinoma (N¼ 165) and squamous
cell carcinoma cases (N¼ 125) who had sufficient tumour tissue
available (Landi et al, 2010).
Laboratory methods
Microarray (N¼ 290) The miRNA expression in adenocarcinoma
and squamous cell carcinoma cases was compared using a custom-
made two-channel oligo-array of 713 human, mammalian, and
viral mature antisense miRNAs including 2 internal controls with 7
serial dilutions starting at 5 mM and ending at a final dilution
of 0.0016mM (http://madb.nci.nih.gov/gal_files/CCDTM-miRNA700-
V3px-A.gal). The miRNA chip included miRNAs for EBV (N¼ 21),
human cytomegalovirus (HCMV; N¼ 8), Kaposi’s sarcoma-
associated herpes virus (KSHV, or human herpesvirus 8; N¼ 12),
and simian virus 40 (SV40; N¼ 1). FlashPage Enriched small RNA,
equivalent to 10 mg of the total RNA from formalin-fixed paraffin-
embedded tissue blocks, and EBV reference samples spiked in with
2.5mM antisense control oligos were labelled with Cy5 and Cy3,
respectively, using mirVana miRNA Labelling Kit (Ambion,
Austin, TX, USA) (Landi et al, 2010). The microarray-based
expression ratio for each miRNA was normalised by dividing it by
the median ratio computed over all miRNAs on the microarray.
This method was selected on the basis of a separate study that
directly compared the performance of several miRNA microarray
normalisation methods (Zhao et al, 2010). Additional details and
results of the human miRNA analyses are published elsewhere
(Landi et al, 2010). Missing microarray data can arise when the
background intensity is greater than the foreground intensity or
when both signals on a dual-channel array are below the specified
minimum threshold (set to 100, as per common practice; Simon
et al, 2004), potentially leading to high levels of missing data. Thus,
analyses included only miRNAs with o50% missing data across all
290 samples.
qPCR (N¼ 48) Using previously described qPCR assay methods
(O’Hara et al, 2008; Xia et al, 2008), we attempted to confirm
selected microarray results. We focussed on EBV miRNAs, which
produced many of the greatest differences in expression by
histology. We selected the EBV BART1 and BART2 pre-miRNAs
because the assays for these two miRNAs were well-validated and
because these pre-miRNAs are further processed to make multiple
individual EBV miRNAs that had been targeted by the microarray.
We also targeted the BHRF1 –3 pre-miRNA as it is representative
of the miRNAs encoded by a different portion of the EBV genome.
We chose 48 RNA samples (25 from adenocarcinoma, 23 from
squamous cell carcinoma) with sufficient material for confirmation
of viral and human miRNA expression as previously described
(Landi et al, 2010). Of each sample, 5 ml was diluted into 40 ml with
RNase-free water. First-strand cDNA was synthesised from 20 ml
RNA using SuperScript First-Strand Synthesis System for qPCR
(Invitrogen, Carlsbad, CA, USA). The EBV BART1, BART2, and
BHRF1–3 primers targeting EBV pre-miRNAs were applied in
replicate with four replicate amplifications per primer pair, for a
total of 12 results in each of 48 specimens, or 576 test results. For
each specimen, the average number of detectable results was
calculated. Specimens with X50% EBV miRNA positivity (at least
6 out of 12 amplifications with detectable EBV miRNA) were
considered to have sufficient evidence for the presence of EBV
miRNA. Primers targeting miR-16 were chosen as an internal
control for miRNA preservation, quality, and amplifiability
because it is expressed consistently in human tissues (Liang
et al, 2007). All qPCR assays were conducted without knowledge of
microarray results. Adequate miRNA recovery was confirmed in
46 out of 48 paraffin-embedded tissues.
Assessment of EBV localisation (N¼ 12) As the EBV miRNA
signal could conceivably come from infiltrating lymphocytes,
histochemical analyses were conducted in tumour tissues from all
cases with sufficient evidence of EBV miRNAs as measured by
qPCR (X50% EBV miRNA positivity) and available tissue (N¼ 6)
and in six cases with little or no evidence of EBV miRNAs (p1 out
of 12 amplifications with detectable EBV miRNA, or o10% EBV
miRNA positivity) to establish whether EBV was localised to
tumour cells. To detect and localise latent infection, in situ
hybridisation (ISH) against EBER was performed on paraffin
sections using the Bond system (Leica Microsystems, Buffalo
Grove, IL, USA) (Lu et al, 2009). RNA preservation was examined
in parallel by oligo-dT ISH as a quality control measure. To detect
lytic infection, immunohistochemistry (IHC) was performed using
antibody against lytic EBV protein BMRF1 (Research Diagnostics
Inc., Flanders, NJ, USA). Infected Hodgkin’s lymphoma was used
as positive control for EBER ISH, and oral hairy leukoplakia was a
positive control for BMRF1 immunostains. Localisation of signal to
tumour vs reactive cells was interpreted by a pathologist. In
addition, qPCR on extracted DNA was performed on an ABI 7500
using primers and a TaqMan probe (Applied Biosystems, Carlsbad,
CA, USA) targeting EBV BamH1W, as previously published (Ryan
et al, 2004). Efficacy of DNA extraction and amplification was
examined by parallel amplification of the human APOB gene. DNA




Class comparisons of lung adenocarcinoma vs squamous cell
carcinoma: Differences between histologies in the expression of
individual viral miRNAs were assessed using normalised data and
two-sided t-tests. Given that we evaluated 32 viral miRNAs, we
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used an a level of 0.01 so that less than one miRNA would be
expected to produce a significant result by chance. Multiple testing
was accounted for in two ways: first, using the Benjamini and
Hochberg method to estimate the false discovery rate (FDR)
(Benjamini and Hochberg, 1995), and second using global
permutation tests with 10 000 permutations, as previously
described (Rotunno et al, 2010), to confirm overall significance
of the expression profile differences. Analyses were also restricted
to male smokers and adjusted by continuous age and stage (I, II,
III, IV) to evaluate the robustness of results.
Correlation between microarray and qPCR: The qPCR DCt (cycle
threshold) was calculated for each EBV miRNA by subtracting the
average of the positive EBV miRNA Cts from the average Ct for
miR-16. Cts 440 were considered missing (undetectable). Similar
ratio measures were created for the microarray expression data by
subtracting the miR-16 log-ratio from the microarray EBV miRNA
log-ratios. The CORR procedure in SAS 9 (SAS Institute Inc., Cary,
NC, USA) was used to calculate Spearman’s rank-order correlation
coefficient and test whether the correlation between the microarray
ratio measures and qPCR DCt equalled zero for each EBV miRNA or
pre-miRNA set. We also conducted sensitivity analyses to see if the
definition of EBV positivity changed the results for correlation.
RESULTS
Of the 2100 lung cancer patients in EAGLE, 290 of the 656 cases
with paraffin-embedded tissue blocks met the inclusion criteria,
and 48 of those were tested for confirmation by qPCR. Among
cases with available tissue, 6 with X50% EBV miRNA positivity by
qPCR and 6 with o10% EBV miRNA positivity by qPCR had
follow-up testing for EBV (Figure 1). The median age for all 290
patients was 67 (range, 39– 80). The distribution of lung
adenocarcinoma and squamous cell carcinoma patients was
similar to that seen in other populations (Ginsberg et al, 2007;
Egleston et al, 2009; Fesinmeyer et al, 2010); adenocarcinoma cases
were somewhat younger, as expected, and more likely to be female
or never smokers than squamous cell carcinoma cases (Table 1).
The majority of samples were from relatively early-stage (I –IIIA)
tumours because surgical tissue samples were collected from
resectable lesions.
Of the 42 viral miRNAs included on the miRNA microarray
chip, 32 had o50% missing data (and 19 had o10% missing data)
across all 290 samples. Most viral miRNAs appeared to be
upregulated in adenocarcinoma compared with squamous cell
carcinoma. The EBV miRNAs were the most common. Of 16 EBV
miRNAs with o50% missing data, 9 (56%) strongly differentiated
between adenocarcinoma and squamous cell carcinoma (para-
metric P-value o0.01; highlighted in bold in Table 2). Results
were similar after adjusting for age and stage and restricting to
male smokers, who made up the majority of cases (Supplementary
Table 1).
Given this evidence that EBV miRNAs could distinguish
between lung cancer histologies, we sought to confirm the
microarray results by conducting qPCR for EBV pre-miRNAs
BART1, BART2, and BHRF1–3 in a subset of cases (n¼ 48)
(Supplementary Table 2). All of the cases considered EBV miRNA
positive (X50% qPCRs positive across all three EBV miRNAs) had
an average Ct of o35 for BART1 (Supplementary Table 2). These
EBV miRNA-positive cases included three patients with adeno-
carcinoma and four with squamous cell carcinoma. EBV miRNA
positivity by qPCR did not distinguish squamous cell carcinoma
from adenocarcinoma among the 48 cases tested by qPCR (w2 P-
value¼ 0.6). Moreover, we found little correlation between
microarray and qPCR for BART1, BART2, and BHRF1–3
expression (Spearman’s correlation coefficients¼ 0.12, 0.03, and
0.37 and P¼ 0.53, 0.94, and 0.47, respectively). All correlation
coefficients were low, suggesting substantial variation between the
two platforms. Correlation coefficients remained low when we
conducted sensitivity analyses using alternative definitions of EBV
miRNA positivity. For example, when we compared the microarray
log-ratio with any EBV miRNA detection by qPCR, the correlation
coefficients were 0.02 (P¼ 0.92) for BART1, 0.03 (P¼ 0.90) for
BART2, 0.21 (P¼ 0.15) for BHRF1–3, and 0.01 (P¼ 0.97) for
miR-16.
To determine whether the EBV genome was present in tumour
tissue from EBV miRNA-positive cases and whether the infection
was located in tumour cells, rather than infiltrating lymphocytes,
follow-up analyses were conducted in six cases with and six cases
without strong evidence of EBV miRNAs (X50% positivity across
all three EBV miRNAs) as measured by qPCR (Table 3). Although
all EAGLE lung cancer diagnoses included in this study were
confirmed by pathology reports from surgery, biopsy, or cytology
samples (Landi et al, 2008), lung tumours are heterogeneous. Thus,
3 of the 12 cases evaluated for evidence of EBV in tumour tissue
(one with sufficient evidence of EBV miRNAs and two without) did
not have identifiable cancer in the remaining tissue samples used
to test for EBER expression (Table 3). Of the remaining nine cases,
none had detectable EBER expression in the malignant cells. One
squamous cell carcinoma case had rare EBER-expressing lymphoid
cells of the stroma but was not positive for any of the three EBV
miRNAs by qPCR. In addition, none of the cases had lytic EBV
infection as measured by IHC targeting the BMRF1 protein.
2100 lung cancer
cases in EAGLE
6 cases‡ with 50% EBV
miR positivity by qPCR
1212 with 1
pathology sample
290* selected to measure
microRNA expression by microarray
48† selected to measure
microRNA expression by qPCR
12 evaluated for EBV DNA, RNA,
and protein in tumour tissue
6 cases with <10% EBV
miR positivity by qPCR
Figure 1 Description of case selection. *Included all adenocarcinoma
and squamous cell carcinoma cases who did not receive chemotherapy or
radiation therapy before the study and had sufficient tissue available of non-
mixed histologies. wIncluded cases with sufficient RNA samples chosen for
confirmation of viral and human miRNA expression as described by Landi
et al (2010). zOf the 48 cases tested by qPCR, 7 cases were positive for
EBV miRNAs (at least 6 out of 12 amplifications with detectable EBV
miRNA). Of these seven cases, six had tissue available for follow-up
analyses.
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All 12 cases had amplifiable human APOB (median, 12 770;
range, 2824– 50 923), indicating successful DNA extraction. Two
cases had EBV DNA detected at low copy number (Table 3). One
was the case with stromal EBER expression, consistent with latent
EBV infection in rare lymphocytes. The other case with evidence of
EBV DNA also had detectable miRNA expression for BART1 in 4
out of 4 replicate qPCRs, BART2 in 3 out of 4 replicates, and
BHRF1 in 1 out of 4 replicates. However, lack of EBER expression
by ISH suggested that latent EBV was not localised to malignant
cells or to surrounding lymphocytes. Nor did this tissue have
detectable BMRF1, a protein indicative of replicative, lytic EBV
infection. Taken together, these results suggest that the EBV DNA
detected in this case did not reflect a typical malignancy-related
EBV infection.
DISCUSSION
There is strong evidence that EBV miRNAs can contribute to
carcinogenesis; EBV miRNAs have been detected in EBV-
associated lymphomas and may affect immune surveillance by
modulating cytotoxic lymphocyte cytokine networks (Xia et al,
2008). The EBV miRNAs can both promote the escape of EBV-
infected cells from host immune surveillance by dysregulating viral
and human gene expression (Lung et al, 2009) and interact with
genes involved in apoptosis pathways, as supported by experi-
mental evidence and computational prediction studies of miRNA/
target pairs (Choy et al, 2008; Lagana et al, 2010). This evidence led
Table 1 Descriptive characteristics of EAGLE patients whose samples






Median age (range) 65 (39–79) 70 (42–80)
Gender
Male 89 (54%) 122 (98%)
Female 76 (46%) 3 (2%)
Smoking, n (%)
Current 70 (42%) 64 (51%)
Formerb 61 (37%) 60 (48%)
Never 34 (21%) 1 (1%)
Average packs per day, median
(25th–75th percentile)c
1.0 (0.75–1.0) 1.0 (1.0–1.5)
Stage, n (%)
IA 32 (19%) 25 (20%)
IB 33 (20%) 27 (22%)
IIA 10 (6%) 4 (3%)
IIB 33 (20%) 38 (30%)
IIIA 32 (19%) 17 (14%)
IIIB 14 (8%) 13 (10%)
IV 11 (7%) 1 (1%)
Abbreviations: EAGLE¼ Environment And Genetics in Lung cancer Etiology;
miRNA¼microRNA. aAdapted from Landi et al (2010). bFormer smokers were
subjects who quit smoking X6 months before the study. cData available for current
and former smokers only.
Table 2 Expression of viral miRNAs in EAGLE patients with lung adenocarcinoma compared with squamous cell carcinoma
MiRNA Unique ID P-valuea FDRb Permutation P-value GM in ADc GM in SQd Fold-change AD/SQe
hcmv-miR-UL70-3p MIMAT0003343 1.00E07 1.60E06 o1e07 0.99 0.68 1.46
ebv-mir-BART8f MIMAT0003418 1.00E07 1.60E06 o1e07 1.04 1.23 0.85
kshv-miR-K12-3 MIMAT0002193 2.00E07 2.10E06 o1e07 1.62 1.18 1.37
ebv-mir-BART4 MIMAT0003412 7.00E07 5.60E06 o1e07 0.47 0.35 1.35
ebv-miR-BART1 MIMAT0000999 1.20E06 7.70E06 o1e07 0.22 0.16 1.39
ebv-miR-BART6-3p MIMAT0003415 4.43E05 2.36E04 o1e07 1.14 0.91 1.25
ebv-miR-BART20-5p MIMAT0003719 1.04E04 4.74E04 1.00E04 1.03 1.20 0.86
ebv-mir-BART3f MIMAT0003410 4.47E04 1.79E03 5.00E04 0.07 0.05 1.50
ebv-mir-BART16 MIMAT0003714 5.91E04 2.10E03 3.00E04 1.09 1.19 0.91
ebv-mir-BART13 MIMAT0003424 7.35E04 2.35E03 o1e07 1.20 1.03 1.17
kshv-miR-K12-8 MIMAT0002186 1.07E03 3.12E03 9.00E04 1.57 1.29 1.21
sv40-miR-S1-5p MIMAT0003344 1.25E03 3.34E03 1.40E03 1.20 1.06 1.13
kshv-miR-K12-10a MIMAT0002179 1.58E03 3.89E03 2.30E03 0.82 0.63 1.30
kshv-miR-K12-10b MIMAT0002180 2.01E03 4.44E03 2.10E03 0.85 0.69 1.22
ebv-miR-BHRF1-3 MIMAT0000998 2.08E03 4.44E03 2.50E03 0.15 0.12 1.29
kshv-miR-K12-1 MIMAT0002182 4.10E03 7.73E03 3.40E03 1.04 1.13 0.92
hcmv-miR-US5-1 MIMAT0001579 4.11E03 7.73E03 3.60E03 0.70 0.63 1.12
ebv-mir-BART14 MIMAT0003426 0.02 0.04 0.02 0.89 0.73 1.21
ebv-mir-BART3 MIMAT0003411 0.05 0.08 0.05 0.36 0.31 1.19
ebv-miR-BART2 MIMAT0001000 0.09 0.15 0.09 0.03 0.03 1.23
kshv-miR-K12-6-5p MIMAT0002188 0.12 0.18 0.12 1.74 1.57 1.10
kshv-miR-K12-5 MIMAT0002190 0.13 0.18 0.12 1.16 1.22 0.95
hcmv-miR-US25-2-5p MIMAT0001582 0.15 0.21 0.15 1.09 1.05 1.05
ebv-mir-BART12 MIMAT0003423 0.16 0.21 0.16 1.06 1.16 0.92
ebv-miR-BART17-5p MIMAT0003715 0.22 0.28 0.22 1.27 1.23 1.04
ebv-mir-BART5 MIMAT0003413 0.23 0.28 0.23 2.91 2.67 1.09
hcmv-miR-UL112-1 MIMAT0001577 0.24 0.28 0.24 1.36 1.31 1.04
hcmv-miR-UL36-1 MIMAT0001576 0.27 0.31 0.27 1.08 1.12 0.96
hcmv-miR-US4 MIMAT0003341 0.35 0.38 0.35 1.07 1.09 0.98
ebv-mir-BART10 MIMAT0003420 0.36 0.38 0.35 1.18 1.11 1.06
kshv-miR-K12-2 MIMAT0002183 0.57 0.59 0.57 0.90 0.94 0.96
kshv-mir-K12-12 MIMAT0003712 0.87 0.87 0.87 1.18 1.17 1.01
Abbreviations: EAGLE¼ Environment And Genetics in Lung cancer Etiology; miRNA¼microRNA; FDR¼ false discovery rate; GM¼ geometric mean; AD¼ adenocarcinoma;
SQ¼ squamous cell carcinoma. MiRNAs are sorted by the parametric P-value from the univariate test. aParametric P-value. bFDR calculated by the method of Benjamini and
Hochberg (1995). cGeometric mean of miRNA expression in AD samples compared with the Epstein –Barr virus (EBV) reference sample. dGeometric mean of miRNA
expression in SQ samples compared with the EBV reference sample. eRatio of geometric mean ratios of miRNA expression in adenocarcinoma/squamous cell carcinoma.
fDenotes the antisense miRNA. Note: bold values indicate EBV miRNAs.
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us to test the hypothesis that viral miRNAs are present in tumour
tissue of lung cancer patients.
Our initial microarray results were promising; most viral
miRNAs were upregulated in adenocarcinoma compared with
squamous cell carcinoma, supporting the hypothesis that infec-
tions may contribute to the development of adenocarcinoma. In
addition, 56% of the analysed EBV miRNAs differentiated between
adenocarcinoma and squamous cell carcinoma, supporting the
hypothesis that EBV may be one such contributing infection.
We tested a subset of samples using qPCR assays previously
demonstrated to detect BART1, BART2, and BHRF miRNA in
EBV-positive primary effusion lymphoma and Burkitt lymphoma
cell lines or tissues but not EBV-negative samples like Kaposi
sarcoma biopsies, immortalised virus-negative endothelial cell
lines, or normal tonsil tissue (O’Hara et al, 2008, 2009a; Xia et al,
2008). However, the qPCR miRNA expression results from these
prevalidated qPCR miRNA assays did not confirm the microarray
results. When we further examined tumour tissue for EBV DNA,
latently expressed EBV EBER RNA, and lytically expressed EBV
BMRF1 protein in cases with and without strong qPCR-based
evidence of EBV miRNAs, we found no evidence of traditional
cancer-related EBV infection in the tumour tissue. Only one
squamous cell carcinoma case had both EBER and EBV DNA
detected, and the EBER expression in this case was localised to rare
lymphocytes, rather than malignant epithelial cells. Although
based on small numbers, these findings do not support the
hypothesis that the EBV genome is present in malignant cells of
EBV miRNA-positive cases. Furthermore, the findings suggest that
EBV miRNA expression, including pre-miRNA and mature miRNA
expression, might not correlate with conventional tissue-based
measures of EBV infection in lung cancer, although it does in
nasopharyngeal carcinoma (NPC) (Cosmopoulos et al, 2009).
The published epidemiologic evidence of EBV-associated lung
cancer has been mixed. The EBV has been localised within the
malignant cells of the rare LELC cases, particularly in Asian cases
(Ho et al, 2006), but the EAGLE study did not include any LELC
cases. The literature is less consistent for other lung histologies.
Two previous serologic studies found a higher seroprevalence of
several EBV antibodies in lung cancer cases compared with healthy
controls (Desgranges and de-The, 1979; Roy et al, 1994). Among
tissue-based studies, some studies have found 5– 10% positivity by
EBER ISH or EBV nuclear antigen IHC (Kasai et al, 1994; Wong
et al, 1995; Grinstein et al, 2002), whereas others have found no
positivity by EBER ISH (Conway et al, 1996; Kijima et al, 2001;
Hayakawa et al, 2003; Chu et al, 2004; Lim et al, 2009) and
generally low or no positivity by other markers (Chu et al, 2004).
Although EBER ISH is considered the gold standard for detecting
EBV-associated cancers because of its high abundance in latently
EBV-infected cells, it is not a perfect measure (Delecluse et al,
2007). Thus, the current study took a more comprehensive
approach than most previous tissue-based studies by using
multiple tests to detect EBV. The PCR of BamH1W DNA represents
a very sensitive assay of the EBV genome by virtue of targeting
a reiterated segment of the EBV genome. In addition, the
histochemical assays permit localisation of the virus to particular
cell types by targeting the latent viral infection using EBER ISH
and lytic viral infection using BMRF1 immunohistochemistry. Our
tissue-based results support those of previous studies suggesting
that EBV is not linked to lung cancer.
One possible explanation for the detection of EBV miRNAs
without corresponding localisation of EBV infection to tumour
cells is that our miRNA detection assays crossreacted with another
target. Potential crossreaction is a general limitation of mature
miRNA assays, as the target size is only B22 nucleotides. Another
explanation is that the assays are so sensitive that even rare
infected cells generate a positive result. Most adults carry EBV in
about one in a million lymphocytes as a consequence of the fact
that the virus persists for life in the human host following primary
infection, and 490% of adults have serologic evidence of EBV
infection (Rickinson and Kieff, 2007). Another explanation may be
delivery of EBV miRNAs from infected lymphocytes to uninfected
lung cells; recent cell line and mouse studies suggest that miRNAs,
including EBV miRNAs, can be secreted in vesicles and delivered
to other cells (Pegtel et al, 2010; Zhang et al, 2010). On the other
hand, EBV miRNAs have been detected in EBER-positive NPC
biopsies but not EBV-negative NPC cell lines (Cosmopoulos et al,
2009), suggesting that EBV miRNA expression is specific for EBV-
infected cells. Even so, the potential for extracellular delivery of
EBV miRNAs without accompanying infection should be explored.
We used qPCR, which is the recommended verification
procedure for microarray miRNA profiling (Croce, 2009), and we
further studied selected cases using microscopy-based histochem-
ical analyses. Although both microarray and qPCR detected EBV
mature miRNA or pre-miRNA expression in some lung cancer
cases, results from these two platforms did not agree with each
other. Such inconsistency between platforms is not uncommon
(Koshiol et al, 2010). It could be because of technical differences in
sensitivity and specificity of the different assays, the amount and
quality of RNA available, or biological differences of the target
molecules. By and large, pre-miRNA levels correlate with mature
miRNA levels for EBV in lymphoma (Jiang et al, 2005; Lee et al,
2008; O’Hara et al, 2008, 2009b). However, it is possible that














1 Yes 1 NCb No No 0
2 Yes 2 No No No 0
3 Yes 0 No No No 0
4 Yes 0 No No No 0
5 Yes NDc No No No 17
6 Yes 3 No No No 0
7 No 1 NCb No No 0
8 No 1 NCb No No 0
9 No 3 No No No 0
10 No 3 No No No 0
11 No 1 No No No 0
12 No 0 No Yesd No 17
Abbreviations: EAGLE¼ Environment And Genetics in Lung cancer Etiology; EBV¼ Epstein –Barr virus; miRNA¼microRNA; IHC¼ immunohistochemistry; ISH¼ in situ
hybridisation. aYes¼ cases with X50% EBV miRNA positivity (at least 6 out of 12 amplifications with detectable EBV miRNA); no¼ cases with o10% EBV miRNA positivity
(p1 out of 12 amplifications with detectable EBV miRNA). bNC¼ no cancer identified in tested specimen. cND¼ tissue lost from slide during ISH, and hence no RNA
preservation control available. dPositivity in lymphoid cells.
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pre-miRNA levels may not correlate with mature miRNA levels
in the lung cancer setting, which might explain the observed
differences between the array platform that targets mature
miRNAs and the qPCR platform that targets pre-miRNAs. In
addition, although most miRNAs are stable, some do decay more
quickly than others in vivo and in vitro (Bail et al, 2010), which
potentially could lead to differences in the microarray and qPCR
assays. Future studies should include a larger number of EBV
miRNAs in methodological evaluations to refine EBV miRNA
expression/detection technology to the point where it may be
reliably employed in epidemiologic studies.
To our knowledge, this is the first study of viral miRNAs in lung
cancer patients. By integrating multiple EBV detection methods
and evaluating latent and lytic viral markers, we have provided a
comprehensive assessment of EBV in the lung cancer cases we
studied. The findings to date do not support a role for EBV in this
disease.
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